Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TELA BioTELA -2.96%52 3-Year ROIIC % is 21,008.00 as of Dec. 2025. GuruFocus rates TELA with a GF Score™ of 52/100 and a GF Value™ of $1.65 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, TELA Bio ranks better than 99.75% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
TELA Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 21,008.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for TELA Bio's 3-Year ROIIC % or its related term are showing as below:
TELA's 3-Year ROIIC % is ranked better than 99.75% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.52
vs TELA: 21008.00
TELA Bio (NAS:TELA) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TELA Bio 3-Year ROIIC % Related Terms
TELA Bio 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for TELA Bio's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA vs NSPR, BDMD, PAVM: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, TELA Bio's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TELA Bio 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TELA Bio's 3-Year ROIIC % falls into.
TELA Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -33.755 (Dec. 2025) - -39.007 (Dec. 2022) )
/
( 20.218 (Dec. 2025) - 20.193 (Dec. 2022) )
=
5.252
/
0.024999999999999
=
21,008.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TELA Bio (TELA) has a 3-Year ROIIC % of 21,008.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TELA Bio and its competitors. According to the industry distribution chart, TELA Bio ranks #2 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 0.3%.
Is TELA Bio's 3-Year ROIIC % too high?
TELA Bio's current 3-Year ROIIC % is 21,008.00. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.52. TELA Bio's value of 21,008.00 is 1382005.3% above this industry median. Based on the distribution chart, TELA Bio ranks #2 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TELA Bio has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's 3-Year ROIIC % compare to NSPR and BDMD?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #2 out of 796 companies for 3-Year ROIIC %. This places TELA Bio in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.52. TELA Bio's value of 21,008.00 is 1382005.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.52, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TELA Bio's current 3-Year ROIIC % of 21,008.00 is 1382005.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TELA Bio and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TELA Bio's current 3-Year ROIIC % is 21,008.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.65, compared to a current price of $0.70 — trading 57.4% below its estimated fair value. The current 3-Year ROIIC % is 21,008.00 and 1382005.3% above the Medical Devices & Instruments industry median of 1.52. TELA Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For TELA Bio (TELA), the current 3-Year ROIIC % is 21,008.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TELA Bio (TELA) Overvalued in 2026?
Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued.
The current stock price of $0.70 is trading 57.4% below its estimated GF Value™ of $1.65.
GuruFocus considers TELA Bio to be Possible Value Trap.
Key valuation signals for TELA:
3-Year ROIIC %: 21,008.00
GF Value™: $1.65 vs. price of $0.70 (57.4% below fair value)
Industry Position: 1382005.3% above the Medical Devices & Instruments median (#2 of 796)
No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
52GF Score
Get the complete analysis for TELA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELA has been successfully added to your 
